• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺侵袭性导管腺癌的基因组分析。

Genomic analysis of aggressive ductal adenocarcinoma of the prostate.

机构信息

Department of Urology, Keio University School of Medicine, Tokyo, Japan.

Department of Urology, Saiseikai Yokohamashi Tobu Hospital, Kanagawa, Japan.

出版信息

Cancer Med. 2023 Apr;12(7):8445-8451. doi: 10.1002/cam4.5573. Epub 2022 Dec 26.

DOI:10.1002/cam4.5573
PMID:36573306
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10134333/
Abstract

BACKGROUND

Genomic profile analysis using next-generation sequencing can potentially elucidate the pathogenesis of rare cancers. Ductal adenocarcinoma, a rare subtype of prostate cancer, has an aggressive nature. This is the first study to analyze the genomic profile of ductal adenocarcinoma in an Asian population.

METHODS

We identified 12 patients newly diagnosed with ductal adenocarcinoma of the prostate at two hospitals, and nine patients (75.0%) had the pure type. Genomic assessment was performed using either the PleSSision testing platform or FoundationOne CDx.

RESULTS

At least one genomic alteration occurred in 11 patients (91.7%), and the most frequently mutated gene was tumor suppressor protein p53 (TP53), which was found in six cases (50.0%). Alterations characteristic of this cohort were found in four cases (33.3%) of retinoblastoma transcriptional corepressor 1 (RB1), which was only observed in the pure type. Compared to previous study results, the frequency of genetic alterations in the phosphoinositide 3-kinase (PI3K) pathway (n = 3; 25.0%) and Wnt-β-catenin pathway (n = 5; 41.7%) was comparable, but no alterations in the DNA damage repair (DDR) pathway were observed. None of the patients presented high tumor mutation burden or microsatellite instability.

CONCLUSIONS

We found that the Asian cohort with ductal adenocarcinoma had actionable alterations, and a high frequency of alterations in TP53 and RB1 reflected the aggressive nature of the tumor. Genetic analysis using next-generation sequencing is expected to help elucidate the pathogenesis of ductal adenocarcinoma.

摘要

背景

下一代测序的基因组分析有可能阐明罕见癌症的发病机制。导管腺癌是前列腺癌的一种罕见亚型,具有侵袭性。这是第一项在亚洲人群中分析导管腺癌基因组特征的研究。

方法

我们在两家医院鉴定了 12 例新诊断的前列腺导管腺癌患者,其中 9 例(75.0%)为纯型。使用 PleSSision 测试平台或 FoundationOne CDx 进行基因组评估。

结果

至少有 11 例患者(91.7%)发生了至少一次基因组改变,最常突变的基因是肿瘤抑制蛋白 p53(TP53),有 6 例(50.0%)发生了改变。在 4 例(33.3%)纯型患者中发现了视网膜母细胞瘤转录核心抑制因子 1(RB1)的特征性改变,这在该队列中仅观察到。与之前的研究结果相比,磷酸肌醇 3-激酶(PI3K)通路(n=3;25.0%)和 Wnt-β-连环蛋白通路(n=5;41.7%)的基因突变频率相当,但未观察到 DNA 损伤修复(DDR)通路的改变。没有患者出现高肿瘤突变负荷或微卫星不稳定。

结论

我们发现亚洲导管腺癌患者存在可治疗的改变,TP53 和 RB1 的高频改变反映了肿瘤的侵袭性。使用下一代测序进行遗传分析有望有助于阐明导管腺癌的发病机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb2a/10134333/cb86497369ce/CAM4-12-8445-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb2a/10134333/cb86497369ce/CAM4-12-8445-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb2a/10134333/cb86497369ce/CAM4-12-8445-g001.jpg

相似文献

1
Genomic analysis of aggressive ductal adenocarcinoma of the prostate.前列腺侵袭性导管腺癌的基因组分析。
Cancer Med. 2023 Apr;12(7):8445-8451. doi: 10.1002/cam4.5573. Epub 2022 Dec 26.
2
Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.下一代测序技术鉴定出了皮脂腺癌中潜在具有临床可操作性的基因突变的高频发生。
J Pathol. 2016 Sep;240(1):84-95. doi: 10.1002/path.4759.
3
Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.局部和转移性前列腺癌中 TP53、PTEN 和 RB1 肿瘤抑制因子的复合基因组改变。
Eur Urol. 2019 Jul;76(1):89-97. doi: 10.1016/j.eururo.2018.11.045. Epub 2018 Dec 12.
4
FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience.日本胰腺导管腺癌患者的 FoundationOne® CDx 基因谱分析:单机构经验。
Surg Today. 2021 Apr;51(4):619-626. doi: 10.1007/s00595-020-02123-2. Epub 2020 Sep 4.
5
Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer.整合基因组分析偶发癌灶提示 CTNNB1 和 PTEN 改变与前列腺导管癌相关。
Eur Urol Focus. 2019 May;5(3):433-442. doi: 10.1016/j.euf.2017.12.003. Epub 2017 Dec 8.
6
RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.RB1 和 TP53 共突变与膀胱癌对免疫检查点抑制剂反应的基因组生物标志物密切相关。
BMC Cancer. 2021 Apr 20;21(1):432. doi: 10.1186/s12885-021-08078-y.
7
A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations.首例具有神经内分泌表型特征的前列腺导管腺癌,伴有 PTEN、RB1 和 TP53 改变。
BMC Med Genomics. 2021 Oct 9;14(1):245. doi: 10.1186/s12920-021-01093-9.
8
Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing.前列腺癌的下一代测序:基因组和途径改变、潜在的可操作性模式,以及临床级检测的相对使用率。
Cancer Biol Ther. 2019;20(2):219-226. doi: 10.1080/15384047.2018.1523849. Epub 2018 Oct 19.
9
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.同时存在 RB1 和 TP53 改变的 EGFR 突变型肺癌具有组织学转化和临床结局不良的风险。
J Thorac Oncol. 2019 Oct;14(10):1784-1793. doi: 10.1016/j.jtho.2019.06.002. Epub 2019 Jun 19.
10
Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma.在结直肠神经内分泌癌的互斥亚组中鉴定高危型人乳头瘤病毒和 Rb/E2F 通路基因组改变。
Mod Pathol. 2019 Feb;32(2):290-305. doi: 10.1038/s41379-018-0131-6. Epub 2018 Sep 20.

引用本文的文献

1
Genomic features of liquid biopsies from patients with prostate cancer with and without ductal adenocarcinoma.患有和未患有导管腺癌的前列腺癌患者液体活检的基因组特征。
J Pathol Clin Res. 2025 May;11(3):e70026. doi: 10.1002/2056-4538.70026.
2
Solitary testicular metastasis post-prostatectomy for prostatic ductal adenocarcinoma: case report and literature review.前列腺导管腺癌前列腺切除术后孤立性睾丸转移:病例报告及文献复习
Front Oncol. 2025 Feb 27;15:1464446. doi: 10.3389/fonc.2025.1464446. eCollection 2025.
3
Cases of consecutive ductal adenocarcinoma of the prostate carrying HRR mutation: case series and literature review.

本文引用的文献

1
Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.胆道癌的临床、基因组和转录组数据分析揭示了特定亚型的免疫特征。
JCO Precis Oncol. 2022 Jun;6:e2100510. doi: 10.1200/PO.21.00510.
2
Wnt/β-catenin signal transduction pathway in prostate cancer and associated drug resistance.前列腺癌中的Wnt/β-连环蛋白信号转导通路及相关耐药性
Discov Oncol. 2021 Oct 10;12(1):40. doi: 10.1007/s12672-021-00433-6.
3
Ductal and acinar components of mixed prostatic adenocarcinoma frequently have a common clonal origin.
携带HRR突变的前列腺导管腺癌连续病例:病例系列及文献综述
Oxf Med Case Reports. 2024 Oct 26;2024(10):omae124. doi: 10.1093/omcr/omae124. eCollection 2024 Oct.
4
Implications of unconventional histological subtypes on magnetic resonance imaging and oncological outcomes in patients who have undergone radical prostatectomy.根治性前列腺切除术患者非典型组织学亚型对磁共振成像和肿瘤学结局的影响。
Sci Rep. 2024 Jun 27;14(1):14868. doi: 10.1038/s41598-024-65681-2.
混合前列腺腺癌的导管和腺泡成分通常具有共同的克隆起源。
Prostate. 2022 Apr;82(5):576-583. doi: 10.1002/pros.24304. Epub 2022 Jan 20.
4
A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations.首例具有神经内分泌表型特征的前列腺导管腺癌,伴有 PTEN、RB1 和 TP53 改变。
BMC Med Genomics. 2021 Oct 9;14(1):245. doi: 10.1186/s12920-021-01093-9.
5
First case of ductal adenocarcinoma of the prostate with MAP3K1 homozygous deletion.首例伴有MAP3K1纯合缺失的前列腺导管腺癌
IJU Case Rep. 2021 Mar 17;4(3):176-179. doi: 10.1002/iju5.12274. eCollection 2021 May.
6
Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma.ARID1A缺陷型卵巢透明细胞癌的治疗策略
Cancers (Basel). 2021 Apr 7;13(8):1769. doi: 10.3390/cancers13081769.
7
Optimizing the diagnosis and management of ductal prostate cancer.优化导管前列腺癌的诊断和管理。
Nat Rev Urol. 2021 Jun;18(6):337-358. doi: 10.1038/s41585-021-00447-3. Epub 2021 Apr 6.
8
Clinical and Biological Features of Neuroendocrine Prostate Cancer.神经内分泌前列腺癌的临床和生物学特征。
Curr Oncol Rep. 2021 Jan 12;23(2):15. doi: 10.1007/s11912-020-01003-9.
9
Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies.导管前列腺癌采用常规疗法预后不良。
Eur Urol. 2021 Feb;79(2):298-306. doi: 10.1016/j.eururo.2020.11.015. Epub 2020 Dec 3.
10
Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing.通过循环肿瘤 DNA 测序分析去势敏感和去势抵抗前列腺癌的基因组改变的比较分析。
J Urol. 2021 Feb;205(2):461-469. doi: 10.1097/JU.0000000000001363. Epub 2020 Sep 8.